Simplifying the path to launch for highly sophisticated therapies
The landscape of cell & gene therapies continues to evolve at breakneck speed.
With hundreds of companies developing new therapies, the market is expected to grow at a rate of 18% over the next decade. So the stakes are higher than ever for CGT companies, even as bringing CGTs to the market is as costly and complicated as ever.
At Two Labs, we provide CGT companies with tested, proven-by-results strategy and implementation that eliminates the variables in launching and managing CGTs. With our team’s combined 100+ years of industry experience and established track record of over 280 consulting engagements – including supporting the development and launch of over 20 cell & gene drugs – we provide a wide range of services that positions CGT innovators for market success.
Having supported over 280 launches, our team has the expertise and experience needed to manage the complex commercialization process from where you are to where you want to go, avoiding costly and time-consuming missteps while supporting the market success of your product.
We have helped bring over 280 biopharma products to market, so we know how to support your team and optimize your state licensing, drug price transparency, compendia data, and EHR visibility in order to differentiate your product to physicians, payers, patients, and other stakeholders.
Two Labs’ Medical Affairs & Communications provides vital support in finding the correct audience for your product’s scientific data and strategic goals to tailor a medical communications plan to your needs.
With specialty products, we help you make the right decisions around your channel strategy, including selecting the right 3PL partner, speciality distributors, and specialty pharmacy partners.
We provide a comprehensive scope of patient support services to help you design and implement a best-in-class patient program and execute a post-launch assessment to ensure customer satisfaction and program optimization.
Our experts are the reason 90% of our clients would recommend Two Labs to a colleague.
Vice President, Commercialization
Courtney has helped launch more than 200 specialty products over the last seven years, and she’s our go-to expert on Specialty Distribution, including retina, ophthalmology, oncology, and cell & gene. With 18+ years of experience in the pharmaceutical industry, she is an expert in exclusive distribution modeling.
Vice President, Commercialization
Kyle’s primary role is to ensure manufacturer partners have the appropriate channel strategy infrastructure in place which in turn will lead to a successful patient and prescriber journey for their products. Kyle’s focus areas at Two Labs include oncology, rare disease, and cell & gene, where he has led several successful launches over the years.
No matter where you are in the process, we’re here to support, advise, and implement key strategies to ensure the success of your product.
Cell and gene therapies are reshaping the industry landscape. In this ebook, Two Labs’ Vice President of Specialty Commercialization, Kyle Felmet, shares much-needed guidance on the effects of the rising number of FDA-approved CGTs, discussing what that growth means for payers and the policy changes that will accompany it.
The main question that sits at the center of the most common licensing questions and obstacles for cell and gene strategies: how do companies license a product that is often never touched by the parties that need to hold the license?
Through every step of the commercial journey, Two Labs is your partner in driving success.
110 Riverbend Avenue, Suite 100
Powell, OH 43065
Phone: (614) 389-4004
Fax: (866) 259-4324
Email: info@twolabs.com
© Copyright 2023 | Powered by PRISM